Spain
About Grifols, S.A.
Grifols, S.A. is a leading plasma therapeutics company operating globally, with a strong presence in Spain, the United States, Canada, and other international markets. The company specializes in developing and manufacturing life-saving plasma-derived medicines and diagnostic solutions.
Key Products & Services
- Immunoglobulins: Used to treat immunodeficiencies.
- Albumin: Restores circulatory volume in conditions like liver cirrhosis, trauma, and severe burns.
- Alpha-1 Proteinase Inhibitor: Treats genetic alpha-1 deficiency.
- Clotting Factors: Includes Factor VIII/von Willebrand factor and Factor IX for hemophilia A, von Willebrand's disease, and hemophilia B.
- Antithrombin III: Addresses hereditary antithrombin deficiency.
- Fostamatinib: A spleen tyrosine kinase inhibitor.
- Biological Sealants: Combines fibrinogen and thrombin to control surgical bleeding.
- Plasma Exchange Therapies: Used in Alzheimer’s disease treatment.
- Diagnostic Solutions: Equipment, reagents, and testing services.
Specialized Therapeutics
- Yimmugo IDP: Immunology drug.
- Yimmugo PTI: Hematology drug.
- Prolastin Vials: Pulmonology drug.
Innovation & Development
Grifols is actively advancing its pipeline with cutting-edge therapies, including:
- Xembify Pre-filled syringes, Gamunex Bags, and FlexBag.
- Xembify Biweekly dosing, Fibrinogen, and VISTASEAL.
- Prolastin-C AADT and Fostamatinib.
- Trimodulin, Alfa-1 AT 15%, and other pre-clinical stage treatments.
Collaborations & Partnerships
The company collaborates with organizations like Canadian Blood Services to supply immunoglobulin, reinforcing its commitment to global healthcare solutions.
Company Background
Founded in 1909, Grifols is headquartered in Barcelona, Spain, and continues to drive innovation in plasma-derived medicines and diagnostics.
